257 related articles for article (PubMed ID: 21712812)
1. A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans.
Tsuboi S; Sutoh M; Hatakeyama S; Hiraoka N; Habuchi T; Horikawa Y; Hashimoto Y; Yoneyama T; Mori K; Koie T; Nakamura T; Saitoh H; Yamaya K; Funyu T; Fukuda M; Ohyama C
EMBO J; 2011 Jun; 30(15):3173-85. PubMed ID: 21712812
[TBL] [Abstract][Full Text] [Related]
2. Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity.
Okamoto T; Yoneyama MS; Hatakeyama S; Mori K; Yamamoto H; Koie T; Saitoh H; Yamaya K; Funyu T; Fukuda M; Ohyama C; Tsuboi S
Mol Med Rep; 2013 Feb; 7(2):359-64. PubMed ID: 23165940
[TBL] [Abstract][Full Text] [Related]
3. MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis.
Suzuki Y; Sutoh M; Hatakeyama S; Mori K; Yamamoto H; Koie T; Saitoh H; Yamaya K; Funyu T; Habuchi T; Arai Y; Fukuda M; Ohyama C; Tsuboi S
Int J Oncol; 2012 Jun; 40(6):1831-8. PubMed ID: 22446589
[TBL] [Abstract][Full Text] [Related]
4. A mechanism for evasion of CTL immunity by altered O-glycosylation of HLA class I.
Sutoh Yoneyama M; Tobisawa Y; Hatakeyama S; Sato M; Tone K; Tatara Y; Kakizaki I; Funyu T; Fukuda M; Hoshi S; Ohyama C; Tsuboi S
J Biochem; 2017 Jun; 161(6):479-492. PubMed ID: 28011817
[TBL] [Abstract][Full Text] [Related]
5. Core 2 β1,6-N-acetylglucosaminyltransferases accelerate the escape of choriocarcinoma from natural killer cell immunity.
Nakamura K; Niimi K; Yamamoto E; Ikeda Y; Nishino K; Suzuki S; Kajiyama H; Kikkawa F
Biochem Biophys Rep; 2021 Jul; 26():100951. PubMed ID: 33644424
[TBL] [Abstract][Full Text] [Related]
6. Implications of altered O-glycosylation in tumour immune evasion.
Itano N
J Biochem; 2019 May; 165(5):387-390. PubMed ID: 30649348
[TBL] [Abstract][Full Text] [Related]
7. Cytoplasmic Citrate Flux Modulates the Immune Stimulatory NKG2D Ligand MICA in Cancer Cells.
Møller SH; Mellergaard M; Madsen M; Bermejo AV; Jepsen SD; Hansen MH; Høgh RI; Aldana BI; Desler C; Rasmussen LJ; Sustarsic EG; Gerhart-Hines Z; Daskalaki E; Wheelock CE; Hiron TK; Lin D; O'Callaghan CA; Wandall HH; Andresen L; Skov S
Front Immunol; 2020; 11():1968. PubMed ID: 32849657
[TBL] [Abstract][Full Text] [Related]
8. Tumor defense systems using O-glycans.
Tsuboi S
Biol Pharm Bull; 2012; 35(10):1633-6. PubMed ID: 23037152
[TBL] [Abstract][Full Text] [Related]
9. N-glycans of core2 beta(1,6)-N-acetylglucosaminyltransferase-I (C2GnT-I) but not those of alpha(1,3)-fucosyltransferase-VII (FucT-VII) are required for the synthesis of functional P-selectin glycoprotein ligand-1 (PSGL-1): effects on P-, L- and E-selectin binding.
Prorok-Hamon M; Notel F; Mathieu S; Langlet C; Fukuda M; El-Battari A
Biochem J; 2005 Nov; 391(Pt 3):491-502. PubMed ID: 15926890
[TBL] [Abstract][Full Text] [Related]
10. Expression of a differentiation antigen and poly-N-acetyllactosaminyl O-glycans directed by a cloned core 2 beta-1,6-N-acetylglucosaminyltransferase.
Bierhuizen MF; Maemura K; Fukuda M
J Biol Chem; 1994 Feb; 269(6):4473-9. PubMed ID: 8308016
[TBL] [Abstract][Full Text] [Related]
11. Suppression of Natural Killer cell NKG2D and CD226 anti-tumour cascades by platelet cloaked cancer cells: Implications for the metastatic cascade.
Cluxton CD; Spillane C; O'Toole SA; Sheils O; Gardiner CM; O'Leary JJ
PLoS One; 2019; 14(3):e0211538. PubMed ID: 30908480
[TBL] [Abstract][Full Text] [Related]
12. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
13. NKG2D functions as an activating receptor on natural killer cells in the common marmoset (Callithrix jacchus).
Watanabe M; Kudo Y; Kawano M; Nakayama M; Nakamura K; Kameda M; Ebara M; Sato T; Nakamura M; Omine K; Kametani Y; Suzuki R; Ogasawara K
Int Immunol; 2014 Nov; 26(11):597-606. PubMed ID: 24860119
[TBL] [Abstract][Full Text] [Related]
14. Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma.
Cox ST; Danby R; Hernandez D; Laza-Briviesca R; Pearson H; Madrigal JA; Saudemont A
Front Immunol; 2018; 9():1282. PubMed ID: 29963042
[TBL] [Abstract][Full Text] [Related]
15. Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation.
Fielding CA; Aicheler R; Stanton RJ; Wang EC; Han S; Seirafian S; Davies J; McSharry BP; Weekes MP; Antrobus PR; Prod'homme V; Blanchet FP; Sugrue D; Cuff S; Roberts D; Davison AJ; Lehner PJ; Wilkinson GW; Tomasec P
PLoS Pathog; 2014 May; 10(5):e1004058. PubMed ID: 24787765
[TBL] [Abstract][Full Text] [Related]
16. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications.
Chitadze G; Bhat J; Lettau M; Janssen O; Kabelitz D
Scand J Immunol; 2013 Aug; 78(2):120-9. PubMed ID: 23679194
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells.
Ferrari de Andrade L; Kumar S; Luoma AM; Ito Y; Alves da Silva PH; Pan D; Pyrdol JW; Yoon CH; Wucherpfennig KW
Cancer Immunol Res; 2020 Jun; 8(6):769-780. PubMed ID: 32209637
[TBL] [Abstract][Full Text] [Related]
18. Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA.
Kloss M; Decker P; Baltz KM; Baessler T; Jung G; Rammensee HG; Steinle A; Krusch M; Salih HR
J Immunol; 2008 Nov; 181(10):6711-9. PubMed ID: 18981088
[TBL] [Abstract][Full Text] [Related]
19. Soluble MICA-NKG2D interaction upregulates IFN-γ production by activated CD3-CD56+ NK cells: potential impact on chronic graft versus host disease.
Boukouaci W; Al-Daccak R; Dulphy N; Lauden L; Amokrane K; Fortier C; Marzais F; Bennabi M; Peffault de Latour R; Socie G; Toubert A; Charron D; Krishnamoorthy R; Tamouza R
Hum Immunol; 2013 Dec; 74(12):1536-41. PubMed ID: 23994587
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 10 decreases MICA expression on melanoma cell surface.
Serrano AE; Menares-Castillo E; Garrido-Tapia M; Ribeiro CH; Hernández CJ; Mendoza-Naranjo A; Gatica-Andrades M; Valenzuela-Diaz R; Zúñiga R; López MN; Salazar-Onfray F; Aguillón JC; Molina MC
Immunol Cell Biol; 2011 Mar; 89(3):447-57. PubMed ID: 20714339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
